Verve Therapeutics (NASDAQ:VERV) Stock Rating Lowered by Lifesci Capital

Verve Therapeutics (NASDAQ:VERV - Get Free Report) was downgraded by research analysts at Lifesci Capital from a "strong-buy" rating to a "hold" rating in a report released on Wednesday, MarketBeat Ratings reports. They presently have a $12.00 price objective on the stock. Lifesci Capital's price target suggests a potential upside of 8.50% from the company's previous close. Lifesci Capital also issued estimates for Verve Therapeutics' Q2 2025 earnings at ($0.71) EPS, Q3 2025 earnings at ($0.71) EPS and Q4 2025 earnings at ($0.70) EPS.

Other research analysts have also issued reports about the stock. Guggenheim raised their price target on shares of Verve Therapeutics from $18.00 to $24.00 and gave the company a "buy" rating in a research report on Tuesday, April 15th. Cantor Fitzgerald raised shares of Verve Therapeutics from a "neutral" rating to an "overweight" rating in a research report on Tuesday, April 15th. Royal Bank Of Canada lowered their price objective on shares of Verve Therapeutics from $17.00 to $15.00 and set an "outperform" rating on the stock in a research report on Tuesday, March 4th. Wall Street Zen raised shares of Verve Therapeutics from a "sell" rating to a "hold" rating in a research report on Thursday, May 22nd. Finally, HC Wainwright lowered shares of Verve Therapeutics from a "buy" rating to a "neutral" rating and set a $13.50 price objective on the stock. in a research report on Wednesday. Six research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat, Verve Therapeutics presently has a consensus rating of "Hold" and a consensus price target of $14.75.

Verve Therapeutics Trading Down 0.5%

Shares of VERV traded down $0.06 during trading hours on Wednesday, reaching $11.06. 7,719,335 shares of the stock traded hands, compared to its average volume of 2,372,272. The stock has a fifty day simple moving average of $5.49 and a 200 day simple moving average of $5.93. Verve Therapeutics has a 52 week low of $2.86 and a 52 week high of $11.41. The company has a market cap of $985.89 million, a price-to-earnings ratio of -5.24 and a beta of 1.67.

Verve Therapeutics (NASDAQ:VERV - Get Free Report) last released its quarterly earnings results on Wednesday, May 14th. The company reported ($0.35) earnings per share for the quarter, beating analysts' consensus estimates of ($0.71) by $0.36. Verve Therapeutics had a negative net margin of 303.64% and a negative return on equity of 35.81%. The company had revenue of $32.98 million for the quarter, compared to analyst estimates of $7.13 million. Analysts predict that Verve Therapeutics will post -2.49 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Verve Therapeutics

Several large investors have recently modified their holdings of the business. BVF Inc. IL increased its stake in shares of Verve Therapeutics by 962.2% in the fourth quarter. BVF Inc. IL now owns 6,904,050 shares of the company's stock worth $38,939,000 after purchasing an additional 6,254,050 shares in the last quarter. Schonfeld Strategic Advisors LLC increased its stake in shares of Verve Therapeutics by 57.4% in the fourth quarter. Schonfeld Strategic Advisors LLC now owns 3,789,379 shares of the company's stock worth $21,372,000 after purchasing an additional 1,382,176 shares in the last quarter. Woodline Partners LP purchased a new position in shares of Verve Therapeutics in the first quarter worth about $12,648,000. T. Rowe Price Investment Management Inc. increased its stake in shares of Verve Therapeutics by 5.9% in the first quarter. T. Rowe Price Investment Management Inc. now owns 2,491,949 shares of the company's stock worth $11,389,000 after purchasing an additional 139,350 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. increased its stake in shares of Verve Therapeutics by 18.5% in the fourth quarter. Jacobs Levy Equity Management Inc. now owns 1,848,071 shares of the company's stock worth $10,423,000 after purchasing an additional 288,678 shares in the last quarter. Hedge funds and other institutional investors own 97.11% of the company's stock.

About Verve Therapeutics

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.